288 related articles for article (PubMed ID: 34114360)
21. Updates of mTOR inhibitors.
Zhou H; Luo Y; Huang S
Anticancer Agents Med Chem; 2010 Sep; 10(7):571-81. PubMed ID: 20812900
[TBL] [Abstract][Full Text] [Related]
22. New potential inhibitors of mTOR: a computational investigation integrating molecular docking, virtual screening and molecular dynamics simulation.
Kist R; Caceres RA
J Biomol Struct Dyn; 2017 Dec; 35(16):3555-3568. PubMed ID: 27860549
[TBL] [Abstract][Full Text] [Related]
23. Recent advances in the discovery of small-molecule ATP competitive mTOR inhibitors: a patent review.
Zask A; Verheijen JC; Richard DJ
Expert Opin Ther Pat; 2011 Jul; 21(7):1109-27. PubMed ID: 21591993
[TBL] [Abstract][Full Text] [Related]
24. Searching for potential mTOR inhibitors: Ligand-based drug design, docking and molecular dynamics studies of rapamycin binding site.
Kist R; Timmers LFSM; Caceres RA
J Mol Graph Model; 2018 Mar; 80():251-263. PubMed ID: 29414044
[TBL] [Abstract][Full Text] [Related]
25. Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.
Rodrik-Outmezguine VS; Okaniwa M; Yao Z; Novotny CJ; McWhirter C; Banaji A; Won H; Wong W; Berger M; de Stanchina E; Barratt DG; Cosulich S; Klinowska T; Rosen N; Shokat KM
Nature; 2016 Jun; 534(7606):272-6. PubMed ID: 27279227
[TBL] [Abstract][Full Text] [Related]
26. Current treatment strategies for inhibiting mTOR in cancer.
Chiarini F; Evangelisti C; McCubrey JA; Martelli AM
Trends Pharmacol Sci; 2015 Feb; 36(2):124-35. PubMed ID: 25497227
[TBL] [Abstract][Full Text] [Related]
27. Kinome-wide selectivity profiling of ATP-competitive mammalian target of rapamycin (mTOR) inhibitors and characterization of their binding kinetics.
Liu Q; Kirubakaran S; Hur W; Niepel M; Westover K; Thoreen CC; Wang J; Ni J; Patricelli MP; Vogel K; Riddle S; Waller DL; Traynor R; Sanda T; Zhao Z; Kang SA; Zhao J; Look AT; Sorger PK; Sabatini DM; Gray NS
J Biol Chem; 2012 Mar; 287(13):9742-9752. PubMed ID: 22223645
[TBL] [Abstract][Full Text] [Related]
28. Structure-based optimization of morpholino-triazines as PI3K and mTOR inhibitors.
Poulsen A; Williams M; Nagaraj HM; William AD; Wang H; Soh CK; Xiong ZC; Dymock B
Bioorg Med Chem Lett; 2012 Jan; 22(2):1009-13. PubMed ID: 22197143
[TBL] [Abstract][Full Text] [Related]
29. Targeting mTOR for fighting diseases: A revisited review of mTOR inhibitors.
Xu T; Sun D; Chen Y; Ouyang L
Eur J Med Chem; 2020 Aug; 199():112391. PubMed ID: 32416459
[TBL] [Abstract][Full Text] [Related]
30. Recent developments of small molecule PI3K/mTOR dual inhibitors.
Liu YN; Wan RZ; Liu ZP
Mini Rev Med Chem; 2013 Dec; 13(14):2047-59. PubMed ID: 24195664
[TBL] [Abstract][Full Text] [Related]
31. Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor.
Hoang B; Frost P; Shi Y; Belanger E; Benavides A; Pezeshkpour G; Cappia S; Guglielmelli T; Gera J; Lichtenstein A
Blood; 2010 Nov; 116(22):4560-8. PubMed ID: 20686120
[TBL] [Abstract][Full Text] [Related]
32. Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.
Martelli AM; Chiarini F; Evangelisti C; Cappellini A; Buontempo F; Bressanin D; Fini M; McCubrey JA
Oncotarget; 2012 Apr; 3(4):371-94. PubMed ID: 22564882
[TBL] [Abstract][Full Text] [Related]
33. Structure and ligand-based design of mTOR and PI3-kinase inhibitors leading to the clinical candidates VS-5584 (SB2343) and SB2602.
Poulsen A; Nagaraj H; Lee A; Blanchard S; Soh CK; Chen D; Wang H; Hart S; Goh KC; Dymock B; Williams M
J Chem Inf Model; 2014 Nov; 54(11):3238-50. PubMed ID: 25317974
[TBL] [Abstract][Full Text] [Related]
34. Optimal induction of myeloma cell death requires dual blockade of phosphoinositide 3-kinase and mTOR signalling and is determined by translocation subtype.
Stengel C; Cheung CW; Quinn J; Yong K; Khwaja A
Leukemia; 2012 Aug; 26(8):1761-70. PubMed ID: 22415553
[TBL] [Abstract][Full Text] [Related]
35. Development of ATP-competitive mTOR inhibitors.
Liu Q; Kang SA; Thoreen CC; Hur W; Wang J; Chang JW; Markhard A; Zhang J; Sim T; Sabatini DM; Gray NS
Methods Mol Biol; 2012; 821():447-60. PubMed ID: 22125084
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis and biological evaluation of novel 9-methyl-9H-purine and thieno[3, 2-d]pyrimidine derivatives as potent mTOR inhibitors.
Yang YY; Wang WL; Hu XT; Chen X; Ni Y; Lei YH; Qiu QY; Tao LY; Luo TW; Wang NY
Bioorg Chem; 2023 Mar; 132():106356. PubMed ID: 36669357
[TBL] [Abstract][Full Text] [Related]
37. The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas.
Gini B; Zanca C; Guo D; Matsutani T; Masui K; Ikegami S; Yang H; Nathanson D; Villa GR; Shackelford D; Zhu S; Tanaka K; Babic I; Akhavan D; Lin K; Assuncao A; Gu Y; Bonetti B; Mortensen DS; Xu S; Raymon HK; Cavenee WK; Furnari FB; James CD; Kroemer G; Heath JR; Hege K; Chopra R; Cloughesy TF; Mischel PS
Clin Cancer Res; 2013 Oct; 19(20):5722-32. PubMed ID: 24030701
[TBL] [Abstract][Full Text] [Related]
38. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
[TBL] [Abstract][Full Text] [Related]
39. Overview of Research into mTOR Inhibitors.
Mao B; Zhang Q; Ma L; Zhao DS; Zhao P; Yan P
Molecules; 2022 Aug; 27(16):. PubMed ID: 36014530
[TBL] [Abstract][Full Text] [Related]
40. Targeting mTOR for the treatment of B cell malignancies.
Lee JS; Vo TT; Fruman DA
Br J Clin Pharmacol; 2016 Nov; 82(5):1213-1228. PubMed ID: 26805380
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
